title: Evolution of an amino acid based prodrug approach: stay tuned.
abstract: Certain acyclic nucleoside phosphonates (ANPs) such as (S)-HPMPC (cidofovir, Vistide) and (S)-HPMPA have been shown to be active against a broad spectrum of DNA and retroviruses. However, their poor absorption as well as their toxicity limit the utilization of these therapeutics in the clinic. Nucleoside phosphonates are poorly absorbed primarily due to the presence of the phosphonic acid group, which ionizes at physiological pH. When dosed intravenously they display dose-limiting nephrotoxicity due to their accumulation in the kidney. To overcome these limitations, nucleoside phosphonate prodrug strategies have taken center stage in the development pathway and a number of different approaches are at various stages of development. Our efforts have focused on the development of ANP prodrugs in which a benign amino acid promoiety masks a phosphonate P-OH via a hydroxyl side chain. The design of these prodrugs incorporates multiple chemical groups (the P-X-C linkage, the amino acid stereochemistry, the C-terminal and N-terminal functional groups) that can be tuned to modify absorption, pharmacokinetic and efficacy properties with the goal of improving overall prodrug performance.
authors: Department of Chemistry, University of Southern California, Los Angeles, California 90089-0744, United States.
authors: Ivan S
authors: IS
authors: Krylov
authors: Boris A
authors: BA
authors: Kashemirov
authors: John M
authors: JM
authors: Hilfinger
authors: Charles E
authors: CE
authors: McKenna
mesh_terms: D000596:Amino Acids / Q000737:chemistry*; D000998:Antiviral Agents / Q000737:chemistry*; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000737:chemistry; D015394:Molecular Structure; D063065:Organophosphonates / Q000737:chemistry*; D011355:Prodrugs / Q000737:chemistry*
chemical_list: D000596:Amino Acids; D000998:Antiviral Agents; D063065:Organophosphonates; D011355:Prodrugs; D003596:Cytosine; D000077404:Cidofovir